Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bausch Health Companies Inc. is a multinational pharmaceutical company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, medical devices, and over-the-counter products. The company operates primarily within the specialty pharmaceuticals, medical aesthetics, gastroenterology, neurology, and ophthalmology industries, serving both prescription and consumer healthcare markets.
The company’s primary revenue drivers include branded prescription drugs, eye health products, and aesthetics devices, with key offerings in gastrointestinal therapies, neurology treatments, and vision care. Bausch Health traces its roots to Bausch & Lomb, founded in 1853, and evolved through multiple acquisitions and restructurings. Formerly known as Valeant Pharmaceuticals International, the company rebranded to Bausch Health in 2018 to emphasize a renewed focus on sustainable growth, compliance, and its core healthcare franchises.
Business Operations
Bausch Health operates through several core business segments, including Bausch + Lomb, Salix Pharmaceuticals, Ortho Dermatologics, International Pharmaceuticals, and Diversified Products. These segments generate revenue through the sale of branded pharmaceuticals, contact lenses, ophthalmic surgical products, dermatology treatments, and gastroenterology therapies. The Bausch + Lomb segment, which was partially spun off through an IPO while remaining majority-owned for a period, represents a significant portion of the company’s historical revenue and asset base.
Operations span both domestic and international markets, with manufacturing, research, and commercial activities across North America, Europe, Asia, and Latin America. The company controls a portfolio of proprietary drug formulations, device technologies, and established pharmaceutical brands. Bausch Health also maintains licensing agreements and distribution partnerships to support market access and product commercialization globally.
Strategic Position & Investments
Bausch Health’s strategic direction centers on strengthening its core franchises, reducing leverage, and investing selectively in high-margin specialty therapeutics. Growth initiatives have included focused R&D investment in gastroenterology and ophthalmology, lifecycle management of existing products, and operational efficiency improvements following years of restructuring.
Notable investments include continued support and eventual separation of Bausch + Lomb, as well as prior acquisitions such as Salix Pharmaceuticals, which remains central to the company’s gastroenterology portfolio. The company has also been involved in emerging therapeutic areas within neurology and medical aesthetics, though expansion is generally disciplined and constrained by balance sheet considerations. Where public disclosures differ on the pace or scale of future investments, data inconclusive based on available public sources.
Geographic Footprint
Bausch Health is headquartered in Canada, with principal executive offices in Laval, Quebec, and significant operational presence in the United States. The company maintains manufacturing plants, research facilities, and commercial organizations across North America, Europe, Asia-Pacific, and Latin America.
International markets contribute a meaningful share of revenue, particularly through established ophthalmology and pharmaceutical brands sold outside the United States. The company’s global footprint supports diversified revenue streams and provides exposure to both developed and emerging healthcare markets, with international operations managed through regionally focused subsidiaries.
Leadership & Governance
Bausch Health is led by an executive team with experience in pharmaceuticals, medical devices, and regulated healthcare markets. The leadership emphasizes operational discipline, compliance, and long-term value creation following the company’s prior period of aggressive acquisition-driven growth.
Key executives include:
- Thomas J. Appio – Chief Executive Officer
- John Paulson – Executive Vice Chairman of the Board
- Paul Herendeen – Chief Financial Officer
- Thomas J. McDonough – Chief Legal Officer
- Damon Noonan – Chief Operating Officer
The company operates under a board-led governance framework aligned with public company standards in both Canada and the United States, with strategic oversight focused on risk management, capital allocation, and regulatory compliance.